NAFLD-Associated Comorbidities in Advanced Stage HCC Do Not Alter the Safety and Efficacy of Yttrium-90 Radioembolization

C Schotten; LP Bechmann; P Manka; J Theysohn; A Dechene; A El Fouly; F Barbato; U Neumann; S Radunz; S Sydor; D Heider; M Venerito; A Canbay; G Gerken; K Herrmann; H Wedemeyer; J Best

doi:10.1159/000501484

NAFLD-Associated Comorbidities in Advanced Stage HCC Do Not Alter the Safety and Efficacy of Yttrium-90 Radioembolization

C Schotten, LP Bechmann, P Manka, J Theysohn, A Dechene (Co-author), A El Fouly, F Barbato, U Neumann, S Radunz, S Sydor, D Heider, M Venerito, A Canbay, G Gerken, K Herrmann, H Wedemeyer, J Best

Department of Internal Medicine VI, Division of Gastroenterology and Endocrinology

Research output: Contribution to journal › Original Article › peer-review

18 Citations (Web of Science)

Original language	English
Pages (from-to)	491-504
Journal	LIVER CANCER
Volume	8
Issue number	6
DOIs	https://doi.org/10.1159/000501484
Publication status	Published - 2019

Keywords

ADVANCED HEPATOCELLULAR-CARCINOMA
FATTY LIVER-DISEASE
NATURAL-HISTORY
RISK-FACTORS
SORAFENIB
SURVIVAL
CHEMOEMBOLIZATION
MICROSPHERES
ALCOHOL
SCORE

Access to Document

10.1159/000501484

Cite this

Schotten, C., Bechmann, LP., Manka, P., Theysohn, J., Dechene, A., El Fouly, A., Barbato, F., Neumann, U., Radunz, S., Sydor, S., Heider, D., Venerito, M., Canbay, A., Gerken, G., Herrmann, K., Wedemeyer, H., & Best, J. (2019). NAFLD-Associated Comorbidities in Advanced Stage HCC Do Not Alter the Safety and Efficacy of Yttrium-90 Radioembolization. LIVER CANCER, 8(6), 491-504. https://doi.org/10.1159/000501484

@article{408195c8d0814c058f2be8751f98e915,

title = "NAFLD-Associated Comorbidities in Advanced Stage HCC Do Not Alter the Safety and Efficacy of Yttrium-90 Radioembolization",

keywords = "ADVANCED HEPATOCELLULAR-CARCINOMA, FATTY LIVER-DISEASE, NATURAL-HISTORY, RISK-FACTORS, SORAFENIB, SURVIVAL, CHEMOEMBOLIZATION, MICROSPHERES, ALCOHOL, SCORE",

author = "C Schotten and LP Bechmann and P Manka and J Theysohn and A Dechene and {El Fouly}, A and F Barbato and U Neumann and S Radunz and S Sydor and D Heider and M Venerito and A Canbay and G Gerken and K Herrmann and H Wedemeyer and J Best",

note = "Dechene: Paracelsus Med Univ Nurnberg, Dept Internal Med 6, Nurnberg, Germany;",

year = "2019",

doi = "10.1159/000501484",

language = "English",

volume = "8",

pages = "491--504",

journal = "LIVER CANCER",

issn = "2235-1795",

number = "6",

}

Schotten, C, Bechmann, LP, Manka, P, Theysohn, J, Dechene, A, El Fouly, A, Barbato, F, Neumann, U, Radunz, S, Sydor, S, Heider, D, Venerito, M, Canbay, A, Gerken, G, Herrmann, K, Wedemeyer, H & Best, J 2019, 'NAFLD-Associated Comorbidities in Advanced Stage HCC Do Not Alter the Safety and Efficacy of Yttrium-90 Radioembolization', LIVER CANCER, vol. 8, no. 6, pp. 491-504. https://doi.org/10.1159/000501484

TY - JOUR

T1 - NAFLD-Associated Comorbidities in Advanced Stage HCC Do Not Alter the Safety and Efficacy of Yttrium-90 Radioembolization

AU - Schotten, C

AU - Bechmann, LP

AU - Manka, P

AU - Theysohn, J

AU - Dechene, A

AU - El Fouly, A

AU - Barbato, F

AU - Neumann, U

AU - Radunz, S

AU - Sydor, S

AU - Heider, D

AU - Venerito, M

AU - Canbay, A

AU - Gerken, G

AU - Herrmann, K

AU - Wedemeyer, H

AU - Best, J

N1 - Dechene: Paracelsus Med Univ Nurnberg, Dept Internal Med 6, Nurnberg, Germany;

PY - 2019

Y1 - 2019

KW - ADVANCED HEPATOCELLULAR-CARCINOMA

KW - FATTY LIVER-DISEASE

KW - NATURAL-HISTORY

KW - RISK-FACTORS

KW - SORAFENIB

KW - SURVIVAL

KW - CHEMOEMBOLIZATION

KW - MICROSPHERES

KW - ALCOHOL

KW - SCORE

U2 - 10.1159/000501484

DO - 10.1159/000501484

M3 - Original Article

C2 - 31799206

SN - 2235-1795

VL - 8

SP - 491

EP - 504

JO - LIVER CANCER

JF - LIVER CANCER

IS - 6

ER -